Cover image of the article: Baseline High Viral Load and Unfavorable Patterns of Alanine Aminotransferase Change Predict Virological Relapse in Patients With Chronic Hepatitis C Genotype 1 or 2 Obtaining Rapid Virological Response During Antiviral Therapy

Image Credit:Hepat Mon

Baseline High Viral Load and Unfavorable Patterns of Alanine Aminotransferase Change Predict Virological Relapse in Patients With Chronic Hepatitis C Genotype 1 or 2 Obtaining Rapid Virological Response During Antiviral Therapy

Authors

Kung-Hung Lin2, Hsien-Chung Yu1,*, Ping-I Hsu1, Wei-Lun Tsai1, Wen-Chi Chen1, Chun-Ku Lin1, Hoi-Hung Chan1, Fong-Wei Tsay1, Kwok-Hung Lai1
2Physical Examination Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
1Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
*Corresponding Author: Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. Tel: +886-73422121, Fax: +886-73468237, samhcyu@gmail.com. Email: samhcyu@gmail.com

Hepatitis Monthly:Vol. 13, issue 10; 11892
Published online:Oct 20, 2013
Article type:Research Article
Received:May 02, 2013
Accepted:Sep 27, 2013
How to Cite:Lin K, Yu H, Hsu P, Tsai W, Chen W, et al. Baseline High Viral Load and Unfavorable Patterns of Alanine Aminotransferase Change Predict Virological Relapse in Patients With Chronic Hepatitis C Genotype 1 or 2 Obtaining Rapid Virological Response During Antiviral Therapy. Hepat Mon. 2013;13(10):11892. doi: https://doi.org/10.5812/hepatmon.11892

Abstract

Background:

Rapid virological response (RVR) strongly predicts sustained virological response (SVR) in patients with chronic hepatitis C (CHC), and abbreviates antiviral therapy in some patients.

Objectives:

To identify factors predicting virological relapse (VR) in CHC patients who attained RVR.

Patients and Methods:

Medical records of 133 CHC patients with an RVR after completing 24 weeks of antiviral therapy (a combination of pegylated interferon-? and ribavirin) were analyzed. Baseline characteristics and on-treatment responses were compared between the patients with an SVR and those with VR. Patients with normal alanine aminotransferase (ALT) levels at weeks 4 and 12 and at the end-of-treatment (EoT) and patients with elevated, but constantly decreasing, ALT levels were classified as having favorable patterns of ALT change. A trend of increasing ALT levels either between weeks 4 and 12 or between weeks 12 and EoT was classified as unfavorable. A high viral load (HVL) was defined as a baseline HCV RNA ? 600000 IU/mL.

Results:

In total, 116 (87.2%) patients had a SVR and 14 (10.5%) had VR. The VR rates were comparable between patients with genotype-1 (13.1%) and genotype-2 infection (8.7%) (P = 0.572). Multivariate analysis revealed that HVL (P = 0.015; odds ratio [OR] = 14.754; 95% confidence interval (CI) = 1.671130.240), and unfavorable ALT patterns (P = 0.039; OR = 4.397; 95% CI = 1.07817.930) independently predicted VR. In subgroup analysis, low viral load (LVL) patients had a minimal VR rate (1.8%). Among the HVL patients, the VR rate of those using peg-IFN-?-2a was relatively low (9.1%). Patients using peg-IFN-?-2b had a slightly higher VR rate (23.8%; P = 0.128), and patients with favorable patterns of ALT changes had a lower VR rate (10.3%) compared to the 53.8% in patients with unfavorable ALT patterns (P = 0.005).

Conclusions:

In southern Taiwan, 24 weeks of antiviral therapy achieved a high SVR rate in patients with CHC attaining RVR, except in the subgroup of patients treated with peg-IFN-?-2b with HVL and on-treatment unfavorable ALT patterns.

Highlights

Full Text

Full text is available in PDF

Copyright

© 2013, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

23
Jun
2015
Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study

Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study

Alessandro Federico,
Mario Masarone,
Marco Romano,
Marcello Dallio,
Valerio Rosato,
Marcello Persico

Federico A, Masarone M, Romano M, Dallio M, Rosato V, et al. Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. Hepat Mon. 2015;15(6):e18640. doi: https://doi.org/10.5812/hepatmon.15(6)2015.18640

23
Jun
2015
Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China

Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China

Qin Wu,
Feng Yu Zhan,
En Qiang Chen,
Cong Wang,
Zhen Zhen Li,
Xue Zhong Lei

Wu Q, Zhan FY, Chen EQ, Wang C, Li ZZ, et al. Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China. Hepat Mon. 2015;15(6):e28836. doi: https://doi.org/10.5812/hepatmon.15(6)2015.28836

30
Sep
2012
Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran

Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran

Najmeh Namazee,
Shahnaz Sali,
Sorour Asadi,
Mostafa Shafiei,
Bita Behnava,
Seyed Moayed Alavian

Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, et al. Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran. Hepat Mon. 2012;12(9):6151. doi: https://doi.org/10.5812/hepatmon.6151

30
Jun
2025
A Study of the Recurrence of Hepatitis C Virus After Achieving a Sustained Virological Response

A Study of the Recurrence of Hepatitis C Virus After Achieving a Sustained Virological Response

Nawfal R Hussein,
Ibrahim Naqid,
Aya R Hussein

Hussein NR, Naqid I, Hussein AR. A Study of the Recurrence of Hepatitis C Virus After Achieving a Sustained Virological Response. J Kermanshah Univ Med Sci. 2025;29(2):e161227. doi: https://doi.org/10.5812/jkums-161227

1
Jan
2015
Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1

Heidar Sharafi,
Seyed Moayed Alavian,
Maryam Keshvari

Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1. Hepat Mon. 2015;15(1):e24955. doi: https://doi.org/10.5812/hepatmon.24955

More by these authors

Kung-Hung LinPubMedScholar
Hsien-Chung YuPubMedScholar
Ping-I HsuPubMedScholar
Wei-Lun TsaiPubMedScholar
Wen-Chi ChenPubMedScholar
Chun-Ku LinPubMedScholar
Hoi-Hung ChanPubMedScholar
Fong-Wei TsayPubMedScholar
Kwok-Hung LaiPubMedScholar
Share
Cited by
Metrics